Foster Victor Wealth Advisors LLC Buys 79,343 Shares of GSK plc (NYSE:GSK)

Foster Victor Wealth Advisors LLC grew its position in shares of GSK plc (NYSE:GSK) by 29.1% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 352,260 shares of the pharmaceutical company’s stock after purchasing an additional 79,343 shares during the quarter. Foster Victor Wealth Advisors LLC’s holdings in GSK were worth $11,776,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Eastern Bank bought a new position in GSK during the third quarter worth $26,000. ST Germain D J Co. Inc. grew its holdings in GSK by 195.5% during the 4th quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company’s stock worth $27,000 after acquiring an additional 522 shares during the period. Sunbelt Securities Inc. raised its position in shares of GSK by 73.8% in the 3rd quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock worth $29,000 after acquiring an additional 302 shares in the last quarter. Concord Wealth Partners lifted its stake in shares of GSK by 231.8% in the 3rd quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company’s stock valued at $32,000 after purchasing an additional 547 shares during the period. Finally, Fortitude Family Office LLC bought a new stake in shares of GSK during the 3rd quarter valued at about $42,000. Institutional investors and hedge funds own 15.74% of the company’s stock.

GSK Stock Down 1.1 %

Shares of NYSE:GSK opened at $35.12 on Wednesday. The stock has a market cap of $72.78 billion, a price-to-earnings ratio of 22.80, a PEG ratio of 1.31 and a beta of 0.63. The business’s 50 day moving average is $33.98 and its 200 day moving average is $37.75. GSK plc has a 12-month low of $31.72 and a 12-month high of $45.92. The company has a quick ratio of 0.53, a current ratio of 0.81 and a debt-to-equity ratio of 0.98.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on GSK shares. Deutsche Bank Aktiengesellschaft downgraded GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Guggenheim downgraded shares of GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. Jefferies Financial Group cut shares of GSK from a “buy” rating to a “hold” rating and reduced their price target for the stock from $53.00 to $39.50 in a report on Tuesday, November 12th. Finally, StockNews.com lowered shares of GSK from a “strong-buy” rating to a “buy” rating in a report on Tuesday, January 21st. Six research analysts have rated the stock with a hold rating, one has given a buy rating and three have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, GSK currently has an average rating of “Moderate Buy” and an average price target of $43.25.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.